Ignite Creation Date:
2024-05-06 @ 8:12 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06284486
Status:
RECRUITING
Last Update Posted:
2024-03-27
First Post:
2024-02-22
Brief Title:
A Multi-Site Break Through Cancer Trial Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-07-31
Start Date Type:
ESTIMATED
Primary Completion Date:
2026-12-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-12-30
Completion Date Type:
ESTIMATED
First Submit Date:
2024-02-22
First Submit QC Date:
February 22 2024
Study First Post Date:
2024-02-29
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-08
Last Update Post Date:
2024-03-27
Last Update Post Date Type:
ACTUAL